Ontrak, Inc. (OTRK) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

5.48 k

Shareholding (Mar 2025)

FII

0.06%

Held by 5 FIIs

DII

99.37%

Held by 1 DIIs

Promoter

0.00%

How big is Ontrak, Inc.?

22-Jun-2025

As of Jun 18, Ontrak, Inc. has a market capitalization of 5.86 million, with net sales of 10.19 million and a net profit loss of 27.92 million over the latest four quarters. Shareholder's funds are at 9.87 million, and total assets amount to 21.07 million.

What does Ontrak, Inc. do?

22-Jun-2025

Ontrak, Inc. is a telehealth-enabled healthcare company utilizing artificial intelligence for outpatient treatment, with recent net sales of $2 million and a net loss of $7 million. It operates in the Pharmaceuticals & Biotechnology industry with a market cap of $5.86 million.

Should I buy, sell or hold Ontrak, Inc.?

22-Jun-2025

Who are in the management team of Ontrak, Inc.?

22-Jun-2025

As of March 2022, the management team of Ontrak, Inc. includes Mr. Terren Peizer as Chairman and CEO, along with Directors Ms. Katherine Quinn and several Independent Directors: Mr. Richard Berman, Mr. Gustavo Giraldo, Mr. Robert Rebak, and Ms. Diane Seloff.

Is Ontrak, Inc. technically bullish or bearish?

20-Sep-2025

As of September 3, 2025, Ontrak, Inc. is in a bearish trend with weak strength, indicated by bearish MACD and KST, despite bullish RSI readings, and has significantly underperformed the S&P 500 with a year-to-date return of -98.21%.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Poor Management Efficiency with a low ROCE of 0%

The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward

Poor long term growth as Operating profit has grown by an annual rate 3.29% of over the last 5 years

Negative results in Mar 25

Risky - Negative EBITDA

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 0 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

1.19

Return on Equity

-601.03%

Price to Book

0.02

Revenue and Profits:

Net Sales:

2 Million

(Quarterly Results - Mar 2025)

Net Profit:

-7 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-99.74%

6 Months

-99.99%

1 Year

-99.99%

2 Years

-100.0%

3 Years

-100.0%

4 Years

-100.0%

5 Years

-100.0%

Ontrak, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is Ontrak, Inc. technically bullish or bearish?

As of 3 September 2025, the technical trend for Ontrak, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength, indicated by the weekly MACD and KST both being bearish, and daily moving averages also signaling a bearish trend. While the weekly and monthly RSI readings are bullish, they are overshadowed by the overall bearish indicators from Bollinger Bands and Dow Theory. The stock has significantly underperformed against the S&P 500, with a year-to-date return of -98.21% compared to the benchmark's 12.22%....

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-24.18%

EBIT Growth (5y)

3.29%

EBIT to Interest (avg)

-4.08

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

1.19

Sales to Capital Employed (avg)

0.75

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

6.09%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.39

EV to EBIT

-0.62

EV to EBITDA

-0.66

EV to Capital Employed

1.18

EV to Sales

1.17

PEG Ratio

Dividend Yield

ROCE (Latest)

-190.66%

ROE (Latest)

-601.03%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 2 Schemes (0.56%)

Foreign Institutions

Held by 5 Foreign Institutions (0.06%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is -35.48% vs 19.23% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is -32.69% vs 7.14% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.00",
          "val2": "3.10",
          "chgp": "-35.48%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.30",
          "val2": "-4.00",
          "chgp": "-32.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.00",
          "val2": "0.80",
          "chgp": "25.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.90",
          "val2": "-5.20",
          "chgp": "-32.69%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,900.30%",
          "val2": "-1,386.80%",
          "chgp": "-151.35%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -14.96% vs -12.41% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 8.60% vs 45.93% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "10.80",
          "val2": "12.70",
          "chgp": "-14.96%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-16.40",
          "val2": "-14.30",
          "chgp": "-14.69%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "7.70",
          "val2": "7.20",
          "chgp": "6.94%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-25.50",
          "val2": "-27.90",
          "chgp": "8.60%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,613.50%",
          "val2": "-1,622.50%",
          "chgp": "0.90%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ

Mar'25

Dec'24

Change(%)

Net Sales

2.00

3.10

-35.48%

Operating Profit (PBDIT) excl Other Income

-5.30

-4.00

-32.50%

Interest

1.00

0.80

25.00%

Exceptional Items

0.00

Consolidate Net Profit

-6.90

-5.20

-32.69%

Operating Profit Margin (Excl OI)

-2,900.30%

-1,386.80%

-151.35%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2025 is -35.48% vs 19.23% in Dec 2024

Consolidated Net Profit

QoQ Growth in quarter ended Mar 2025 is -32.69% vs 7.14% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

10.80

12.70

-14.96%

Operating Profit (PBDIT) excl Other Income

-16.40

-14.30

-14.69%

Interest

7.70

7.20

6.94%

Exceptional Items

-0.30

0.00

Consolidate Net Profit

-25.50

-27.90

8.60%

Operating Profit Margin (Excl OI)

-1,613.50%

-1,622.50%

0.90%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -14.96% vs -12.41% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 8.60% vs 45.93% in Dec 2023

All Annual Results

Company CV

About Ontrak, Inc.

Ontrak, Inc.

Pharmaceuticals & Biotechnology

Ontrak, Inc., formerly Catasys, Inc., is an artificial intelligence (AI)-powered and telehealth-enabled, virtualized outpatient healthcare treatment company. Its Ontrak PRE (Predict-Recommend-Engage) platform predicts people whose chronic disease will improve with behavior change, recommends care pathways that people are willing to follow, and engages people who aren’t getting the care they need. The Company’s integrated, technology-enabled OnTrak solution, which is designed to identify and treat members with behavioral conditions that cause or exacerbate chronic medical conditions such as diabetes, hypertension, coronary artery disease, chronic obstructive pulmonary disease, and congestive heart failure. OnTrak integrates evidence-based psychosocial and medical interventions delivered either in-person or via telehealth, along with care coaching and in-market Community Care Coordinators who address the social and environmental determinants of health, including loneliness.

Company Coordinates

Company Details

2120 COLORADO AVE, SUITE 230 , SANTA MONICA CA : 90404

Tel: 1 310 44443001 310 444-4346

http://catasys.com/

Registrar Details

Ontrak, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Ontrak, Inc.?

Watch in Real-Time

What does Ontrak, Inc. do?

Should I buy, sell or hold Ontrak, Inc.?

Who are in the management team of Ontrak, Inc.?

Is Ontrak, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Poor Management Efficiency with a low ROCE of 0%

Poor long term growth as Operating profit has grown by an annual rate 3.29% of over the last 5 years

Negative results in Mar 25

Risky - Negative EBITDA

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is Ontrak, Inc. technically bullish or bearish?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Ontrak, Inc.

Company Coordinates